{"id":8169,"date":"2023-08-04T11:53:14","date_gmt":"2023-08-04T11:53:14","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8169"},"modified":"2023-08-04T11:53:14","modified_gmt":"2023-08-04T11:53:14","slug":"butyrophilin-like-proteins-other-immune-checkpoint-proteins","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/butyrophilin-like-proteins-other-immune-checkpoint-proteins\/","title":{"rendered":"Butyrophilin-like Proteins & Other Immune Checkpoint Proteins"},"content":{"rendered":"\n

Butyrophilin-like 2 [BTNL2]<\/strong><\/h3>\n\n\n\n

Human immunoglobulin (Ig) superfamily receptor proteins of the structural and functional diverse butyrophilin and butyrophilin-like families, termed BTN and BTNL, are recognised as potentially important immune modulators. Butyrophilin family members have been shown to have high homology to the B7 costimulatory molecules and include molecules such as BTN3A1 (CD277), myelin oligodendrocyte glycoprotein (MOG) and mouse Skint1 and Btnl2.<\/p>\n\n\n\n

Butyrophilin-like 2 recognises a putative receptor whose expression on B and T cells is significantly enhanced after activation.\u00a0Butyrophilin-like 2 inhibits T cell proliferation and TCR activation of NFAT, NF-\u03baB and AP-1 signalling pathways. BTNL2 is the first member of the butyrophilin family shown to regulate T cell activation, which has implications in immune diseases and immunotherapy.<\/p>\n\n\n\n

LIT:<\/strong>\u00a0Immune modulation by butyrophilins: H.A. Arnett & J.L. Viney; Nat. Rev. Immunol.\u00a014,<\/strong>\u00a0559 (2014) \u2022 Novel Immune Check-Point Regulators in Tolerance Maintenance: Y. Guo & A.Y. Wang; Front. Immunol.\u00a06,<\/strong>\u00a0421 (2015) \u2022 Regulation of Immunity by Butyrophilins: D.A. Rhodes, et al.; Annu. Rev. Immunol.\u00a034,<\/strong>\u00a0151 (2016)\u00a0<\/p>\n\n\n\n

Biologically Active\u00a0BTNL2 Protein<\/strong><\/p>\n\n\n\n

BTNL2 (mouse):Fc (mouse) (rec.) – CHI-MF-110BTNL2<\/a><\/p>\n\n\n\n

Other Immune Checkpoint Proteins – CD27, CD48, CD200 and CD244<\/strong><\/p>\n\n\n\n

Binding of CD27 [TNFRSF7], a member of the TNF receptor family, with its ligand CD70 [CD27L; TNFRSF5], results in a potent signal to activate and differentiate T cells into effector and memory cells and to boost B cells. However, despite its wide spectrum of action, this pathway has not been demonstrated to be particularly effective in overcoming the immunosuppressive features of the tumour microenvironment and CD27 is considered most useful combined with other pathways.<\/p>\n\n\n\n

CD48 is involved in regulating T cell activation, cell adhesion and co-stimulation through interactions with its ligands CD2 and CD244 [2B4]. On antigen-presenting cells (APCs), CD48 promotes immune synapse organisation and T cell costimulation through binding to CD2 on T cells. Interactions between CD48 and CD244 regulate target cell lysis by NK cells and CTLs as well as effector and memory T cell responses. CD200 is an immune checkpoint protein related to the B7 family of co-stimulatory receptors required for T cell activation and signalling.<\/p>\n\n\n\n

CD200 is expressed on the surface of tumour cells and can be released in a soluble form when cleaved by metalloproteases such as ADAM28 (A disintegrin and metalloprotease 28). Plasma levels of soluble CD200 correlate with tumour burden and survival in CLL patients. Interaction between cancer-released CD200 and its inhibitory receptor (CD200R1) on APCs suppresses the secretion of pro-inflammatory cytokines, including interleukin-2 (IL-2) and interferon-\u03b3 (IFN\u03b3) increases production of myeloid-derived suppressor cells and regulatory T cells (Tregs) and compromises an antitumour immune response.<\/p>\n\n\n\n

Biologically Active\u00a0CD27, CD200 and CD244 Proteins<\/strong><\/p>\n\n\n\n

Biologically Active\u00a0CD27 Proteins\u00a0by Chimerigen CHI-HR-200CD27<\/a> and CHI-HF-210CD27<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0CD27 Proteins by Ancell\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0CD200 Proteins\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0CD244 Proteins here<\/a>.<\/p>\n\n\n\n

VALIDATED\u00a0Antibodies for CD27 and CD48 Research<\/strong><\/p>\n\n\n\n

See all VALIDATED\u00a0Antibodies for CD27 Research here<\/a>.<\/p>\n\n\n\n

See all VALIDATED\u00a0Antibodies for CD48 Research here<\/a>.<\/p>\n\n\n\n

\n
Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

Originally posted on\u00a0adipogen.com\/butyrophilin-like-proteins-other-immune-checkpoint-proteins\/<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Human Ig superfamily receptor proteins of the structural & functional diverse BTN & BTNL families are potentially important immune modulators.<\/p>\n","protected":false},"author":13,"featured_media":7886,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,637],"tags":[279,185,7,683,685],"class_list":["post-8169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-t-cells","tag-adipogen","tag-antibodies","tag-cancer","tag-proteins","tag-t-cells-2"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8169"}],"version-history":[{"count":3,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8169\/revisions"}],"predecessor-version":[{"id":8173,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8169\/revisions\/8173"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/7886"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}